SlidesetViral Hepatitis and Liver DiseaseIntroduction of Simplification- Jordan Feld, MD, MPHView Slideset
SlidesetViral Hepatitis and Liver DiseaseWHO / Perspective on the Simplification Strategies- Philippa Easterbrook, MD, FRCP, MPH, DTM&HView Slideset
SlidesetViral Hepatitis and Liver DiseaseWHA / Community Perspective on the Need for Simplification- Michael NinburgView Slideset
SlidesetViral Hepatitis and Liver DiseaseCanada’s Experience with Needle Exchange Programs- Mark Tyndall, MD, ScD, FRCPCView Slideset
SlidesetViral Hepatitis and Liver DiseaseMonitoring and Testing, Introductory Lecture- Manal El-Sayed, MD, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseUse of the HBV Viral Load Medical Prescription as a Preliminary Assessment of HBV Infection Burden in New Caledonia: a 2014-2019 Retrospective Study- P. DényView Slideset
SlidesetViral Hepatitis and Liver DiseaseMortality from Liver Diseases Associated with Hepatitis B and C in the EU/EEA – Descriptive Analysis and Estimation of 2015 Baseline- O. MårdhView Slideset
SlidesetViral Hepatitis and Liver DiseaseThe Uptake of an Innovative Approach to Reduce HCV Transmission among MSM: the NoMoreC Project- T. PrinsenbergView Slideset
SlidesetViral Hepatitis and Liver DiseaseModel for Care - Focus on HBV, Introductory Lecture- Jordan Feld, MD, MPHView Slideset
SlidesetViral Hepatitis and Liver DiseaseEmergency Department Screening: Strategy for Elimination through an Innovative HBV and HCV Screening, Care, and Cure Program- S. WangView Slideset
SlidesetViral Hepatitis and Liver DiseaseRwanda’s Model for Care- Jean Damascene Makuza, MDView Slideset
SlidesetViral Hepatitis and Liver DiseaseChanges of the Composition of the Hepatitis B Virus (HBV) surface Antigen (HBsAg) are Associated with HBsAg Loss during Nucleos(tid)e Analogues and Peg-interferon-alfa2a Treatment- M. PfefferkornView Slideset
SlidesetViral Hepatitis and Liver DiseaseModel for Care - Focus on HCV, Introductory Lecture- Margaret Hellard, AM, MBBS, FRACP, FAFPHM, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseEvaluation of the Hepatitis C Care Cascade in the Country of Georgia: Monitoring Progress towards Elimination- T. TsertsvadzeView Slideset
SlidesetViral Hepatitis and Liver DiseaseStrategies towards Elimination of Hepatitis C in Iceland: Models of Care for the Treatment as Prevention for Hepatitis C (TraP HeP C) Program- M. GottfredssonView Slideset
SlidesetViral Hepatitis and Liver DiseaseMicro-Elimination of Hepatitis C amongst People Living with HIV (PLHIV) in Punjab, India- P. KatapurView Slideset
SlidesetViral Hepatitis and Liver DiseaseIntegration of Hepatitis C Treatment Services with Harm Reduction Service Centers for People who Inject Drugs in Kenya: Experience from Test and Link to Care for Injecting Drug Users Study- M. NyakowaView Slideset
SlidesetViral Hepatitis and Liver DiseaseTowards the Elimination of HCV in British Columbia: A strategy to Address the “messy middle”- B. ConwayView Slideset
SlidesetViral Hepatitis and Liver DiseaseReal-World Challenges to and Opportunities for Microelimination in Two Remote Communities in Northwestern Ontario- D. SmooklerView Slideset
SlidesetViral Hepatitis and Liver DiseasePolicy Implementation Index Based off of Patient Reported Outcomes: The Hep-CORE Study- A. PalayewView Slideset
SlidesetViral Hepatitis and Liver DiseaseMongolia’s Model for Care- Naranjargal Dashdorj, MD, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseHepatitis C Elimination in the Netherlands (CELINE): a Nationwide Study Retrieving Lost to Follow-Up Chronic Hepatitis C Patients- M. Van DijkView Slideset
SlidesetViral Hepatitis and Liver DiseaseOral Prescription Opioid Use should be Considered a Risk Factor for HCV Infection: Another Step Toward HCV Elimination- B. HackView Slideset
